Apoptotic circulating tumor cells in early and metastatic breast cancer patients

Molecular Cancer Therapeutics

Volumn 12, Issue 9, 2013, Pages 1886-1895

  Kallergi, Galatea ^a   Konstantinidis, Georgios ^a   Markomanolaki, Harris ^a   Papadaki, Maria A ^a   Mavroudis, Dimitris ^a,b   Stournaras, Christos ^a   Georgoulias, Vassilis ^a,b   Agelaki, Sofia ^a,b  

^a UNIVERSITY OF CRETE   (Greece)

^b UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKERATIN; KI 67 ANTIGEN;

APOPTOSIS; ARTICLE; BREAST CANCER; BREAST METASTASIS; CANCER PATIENT; CELL PROLIFERATION; CELL SURVIVAL; CIRCULATING TUMOR CELL; CONTROLLED STUDY; EARLY CANCER; HUMAN; HUMAN CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL;

ADULT; AGED; ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CASPASES; CELL LINE, TUMOR; CELL PROLIFERATION; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; MCF-7 CELLS; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASTIC CELLS, CIRCULATING;

EID: 84884512463     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-12-1167     Document Type: Article

References (39)

1. Kaiser J. Medicine. Cancer's circulation problem. Science 2010;327: 1072-4.
2. Stathopoulou A, Vlachonikolis I, Mavroudis D, Perraki M, Kouroussis C, Apostolaki S, et al. Molecular detection of cytokeratin-19-positive cells in the peripheral blood of patients with operable breast cancer: evaluation of their prognostic significance. J Clin Oncol 2002;20: 3404-12.
3. Xenidis N, Perraki M, Kafousi M, Apostolaki S, Bolonaki I, Stathopoulou A, et al. Predictive and prognostic value of peripheral blood cytokeratin-19 mRNA-positive cells detected by real-time polymerase chain reaction in node-negative breast cancer patients. J Clin Oncol 2006;24:3756-62.
4. Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004;351:781-91.
5. Braun S, Harbeck N. Molecular markers of metastasis in breast cancer: current understanding and prospects for novel diagnosis and prevention. Expert Rev Mol Med 2001;3:1-14.
6. Weinberg RA. Leaving home early: reexamination of the canonical models of tumor progression. Cancer Cell 2008;14:283-4.
7. Klein CA, Blankenstein TJ, Schmidt-Kittler O, Petronio M, Polzer B, Stoecklein NH, et al. Genetic heterogeneity of single disseminated tumour cells in minimal residual cancer. Lancet 2002;360:683-9.
8. Chimonidou M, Strati A, Tzitzira A, Sotiropoulou G, Malamos N, Georgoulias V, et al. DNA methylation of tumor suppressor and metastasis suppressor genes in circulating tumor cells. Clin Chem 2011;57:1169-77.
9. Mavroudis D. Circulating cancer cells. Ann Oncol 2010; Suppl 7: vii95-100.
10. Fidler IJ. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer 2003;3:453-8.
11. Larson CJ, Moreno JG, Pienta KJ, Gross S, Repollet M, O'hara SM, et al. Apoptosis of circulating tumor cells in prostate cancer patients. Cytometry A 2004;62:46-53.
12. Marrinucci D, Bethel K, Bruce RH, Curry DN, Hsieh B, Humphrey M, et al. Case study of the morphologic variation of circulating tumor cells. Hum Pathol 2007;38:514-9.
13. Wimberger P, Heubner M, Otterbach F, Fehm T, Kimmig R, Kasimir- Bauer S. Influence of platinum-based chemotherapy on disseminated tumor cells in blood and bone marrow of patients with ovarian cancer. Gynecol Oncol 2007;107:331-8.
14. Fehm T, Becker S, Becker-Pergola G, Sotlar K, Gebauer G, Durr- Storzer S, et al. Presence of apoptotic and nonapoptotic disseminated tumor cells reflects the response to neoadjuvant systemic therapy in breast cancer. Breast Cancer Res 2006;8:R60.
15. Ausch C, Buxhofer-Ausch V, Olszewski U, Schiessel R, Ogris E, Hinterberger W, et al. Circulating cytokeratin 18 fragment m65-a potential marker of malignancy in colorectal cancer patients. J Gastrointest Surg 2009;13:2020-6.
16. Hou JM, Greystoke A, Lancashire L, Cummings J, Ward T, Board R, et al. Evaluation of circulating tumor cells and serological cell death biomarkers in small cell lung cancer patients undergoing chemotherapy. Am J Pathol 2009;175:808-16.
17. Kramer G, Erdal H, Mertens HJ, Nap M, Mauermann J, Steiner G, et al. Differentiation between cell death modes using measurements of different soluble forms of extracellular cytokeratin 18. Cancer Res 2004;64:1751-6.
18. Xenidis N, Ignatiadis M, Apostolaki S, Perraki M, Kalbakis K, Agelaki S, et al. Cytokeratin-19 mRNA-positive circulating tumor cells after adjuvant chemotherapy in patients with early breast cancer. J Clin Oncol 2009;27:2177-84.
19. Kallergi G, Mavroudis D, Georgoulias V, Stournaras C. Phosphorylation of FAK, PI-3K, and impaired actin organization in CK-positive micrometastatic breast cancer cells. Mol Med 2007;13:79-88.
20. Kallergi G, Agelaki S, Kalykaki A, Stournaras C, Mavroudis D, Georgoulias V. Phosphorylated EGFR and PI3K/Akt signaling kinases are expressed in circulating tumor cells of breast cancer patients. Breast Cancer Res 2008;10:R80.
21. Muller V, Stahmann N, Riethdorf S, Rau T, Zabel T, Goetz A, et al. Circulating tumor cells in breast cancer: correlation to bone marrow micrometastases, heterogeneous response to systemic therapy and low proliferative activity. Clin Cancer Res 2005;11:3678-85.
22. Hou JM, Krebs MG, Lancashire L, Sloane R, Backen A, Swain RK, et al. Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer. J Clin Oncol 2012;30:525-32.
23. Stott SL, Lee RJ, Nagrath S, Yu M, Miyamoto DT, Ulkus L, et al. Isolation and characterization of circulating tumor cells from patients with localized and metastatic prostate cancer. Sci Transl Med 2010;2:25ra23.
24. Tang D, Lahti JM, Kidd VJ. Caspase-8 activation and bid cleavage contribute to MCF7 cellular execution in a caspase-3-dependent manner during staurosporine-mediated apoptosis. J Biol Chem 2000;275:9303-7.
25. Smolewski P, Grabarek J, Lee BW, Johnson GL, Darzynkiewicz Z. Kinetics of HL-60 cell entry to apoptosis during treatment with TNFalpha or camptothecin assayed by the stathmo-apoptosis method. Cytometry 2002;47:143-9.
26. Bedner E, Smolewski P, Amstad P, Darzynkiewicz Z. Activation of caspases measured in situ by binding of fluorochrome-labeled inhibitors of caspases (FLICA): correlation with DNA fragmentation. Exp Cell Res 2000;259:308-13.
27. Deng G, Herrler M, Burgess D, Manna E, Krag D, Burke JF. Enrichment with anti-cytokeratin alone or combined with anti-EpCAM antibodies significantly increases the sensitivity for circulating tumor cell detection in metastatic breast cancer patients. Breast Cancer Res 2008;10:R69.
28. Kallergi G, Papadaki MA, Politaki E, Mavroudis D, Georgoulias V, Agelaki S. Epithelial to mesenchymal transition markers expressed in circulating tumour cells of early and metastatic breast cancer patients. Breast Cancer Res 2011;13:R59.
29. Meng S, Tripathy D, Frenkel EP, Shete S, Naftalis EZ, Huth JF, et al. Circulating tumor cells in patients with breast cancer dormancy. Clin Cancer Res 2004;10:8152-62.
30. Lobodasch K, Frohlich F, Rengsberger M, Schubert R, Dengler R, Pachmann U, et al. Quantification of circulating tumour cells for the monitoring of adjuvant therapy in breast cancer: an increase in cellnumber at completion of therapy is a predictor of early relapse. Breast 2007;16:211-8.
31. Cristofanilli M, Hayes DF, Budd GT, Ellis MJ, Stopeck A, Reuben JM, et al. Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol 2005;23:1420-30.
32. Paterlini-Brechot P, Benali NL. Circulating tumor cells (CTC) detection: clinical impact and future directions. Cancer Lett 2007;253:180-204
33. Mehes G, Witt A, Kubista E, Ambros PF. Circulating breast cancer cells are frequently apoptotic. Am J Pathol 2001;159:17-20.
34. Racila E, Euhus D, Weiss AJ, Rao C,McConnell J, Terstappen LW, et al. Detection and characterization of carcinoma cells in the blood. Proc Natl Acad Sci U S A 1998;95:4589-94.
35. Swennenhuis JF, Tibbe AG, Levink R, Sipkema RC, Terstappen LW. Characterization of circulating tumor cells by fluorescence in situ hybridization. Cytometry A 2009;75:520-7.
36. Weigel MT, Dowsett M. Current and emerging biomarkers in breast cancer: prognosis and prediction. Endocr Relat Cancer 2010;17: R245-R262.
37. Hayes DF, Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Miller MC, et al. Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression- free and overall survival. Clin Cancer Res 2006;12: 4218-24.
38. Dawood S, Cristofanilli M. Integrating circulating tumor cell assays into the management of breast cancer. Curr Treat Options Oncol 2007;8: 89-95.
39. Pachmann K, Camara O, Kavallaris A, Schneider U, Schunemann S, Hoffken K. Quantification of the response of circulating epithelial cells to neodadjuvant treatment for breast cancer: a new tool for therapy monitoring. Breast Cancer Res 2005;7:R975-R979.